Ncardia – which was established in September 2017 following the merger of Pluriomics and Axiogenesis – provides standardized, validated induced pluripotent stem cell (iPSC) assays for safety, phenotypic screening, and disease modeling.
The company’s product portfolio encompasses a panel of hiPSC derived cryopreserved cardiomyocytes and neurons. It also delivers the CardioPlate product line of quality controlled ready to use assay plates.
The agreement – financial terms of which were not disclosed – is the second for Ncardia in the past two months. In October, the company announced a license agreement with Roche, Ncardia’s first pharmaceutical partner.
As part of the agreement, Roche has a worldwide license to Ncardia’s disease modeling patents to further discovery and development of novel drug candidates.
The company also completed a €10.5m ($12.42) Series B financing round in November.